Dabrafenib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 50 mg ,75 mg
Reference Brands: Tafinlar (USA/EU)
Category:
Oncology Cancer Care
Dabrafenib is available in Capsules
and strengths such as 50 mg ,75 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dabrafenib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dabrafenib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dabrafenib is a targeted anticancer medication used for the treatment of cancers that carry specific BRAF gene mutations, particularly the BRAF V600E mutation. It works as a BRAF kinase inhibitor, blocking the abnormal B-Raf protein that drives uncontrolled cell growth and tumor development in mutation-positive cancers. By inhibiting this signaling pathway, dabrafenib helps slow or stop the growth of cancer cells.
It is used as a single agent for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation and is also widely used in combination with the MEK inhibitor trametinib for broader mutation-positive cancers. Combination therapy is approved for indications including metastatic melanoma, metastatic non-small cell lung cancer, anaplastic thyroid cancer, and certain other unresectable or metastatic solid tumors with BRAF V600E mutation. Treatment selection is based on confirmed molecular testing. Dabrafenib is marketed under the brand name Tafinlar and is prescribed under oncology specialist supervision, with regular monitoring to manage safety and treatment response. It represents an important precision therapy option in mutation-driven cancer care.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing